By Chris Thomas
BENGALURU (Reuters) - Indian shares touched a record high on Wednesday, driven by gains in heavyweight Reliance Industries, as hopes for vaccine approvals in the second worst coronavirus-hit country boosted investor sentiment.
The NSE Nifty 50 index rose 0.69% to 13,485.75 by 0446 GMT and was headed for a seventh consecutive session of gains, while the benchmark S&P BSE Sensex was up 0.72% at 45,938.47. Both have hit record highs in 14 of the last 21 sessions and are up 4% so far in December.
India's federal health secretary said on Tuesday the country may approve some coronavirus vaccines over the next few weeks and an estimated 300 million people would be inoculated in the first tranche.
India has the world's second-highest virus caseload behind the United States, but daily cases have stayed below the 50,000-mark since Nov. 8, despite a busy festival season that saw crowded markets and streets.
"The vaccine news is a sentiment booster. But it is gushing liquidity that is supporting markets, we are seeing risk-on sentiment building up globally," said Aishvarya Dadheech, fund manager at Ambit Asset Management in Mumbai.
"I believe markets will see traction building over the next 1-1/2 to two years as the economy recovers from the pandemic," Dadheech said.
Consumer goods giant ITC Ltd climbed 2.3% to its highest since Aug. 11, while index heavyweight Reliance Industries Ltd added 1.1% and top private-sector lender HDFC Bank Ltd rose nearly 1%.
Prestige Estates Ltd rose as much as 4.6% after India's competition regulator approved https://twitter.com/CCI_India/status/1336281154635239426?s=20 the acquisition of some Prestige assets by affiliates of Blackstone Group.
Global equities traded higher on Wednesday, after Britain started mass-vaccinating its people using a fully-tested COVID-19 shot and as Johnson & Johnson said it could obtain late-stage trial results for a single-dose vaccine earlier than expected.
(Reporting by Chris Thomas in Bengaluru; Editing by Ramakrishnan M.)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU